Skin in the Game: Why Dermatology Defies a Cooldown in Healthcare M&A

CHARLOTTE, N.C. – July 28, 2026 – In a year where caution has chilled much of the healthcare investment landscape, one sector is proving remarkably resilient: dermatology. While broader healthcare services M&A activity saw a 16% year-over-year decline in the first half of 2026, the market for dermatology practices has remained robust, buoyed by a unique confluence of fresh capital, shifting investor strategy, and a complex new regulatory map.

A new report from M&A advisory firm TUSK Practice Sales illuminates the forces sustaining this momentum. The analysis reveals a market where private equity (PE) demand is not just holding steady but is being reshaped by a wave of maturing investments and a growing patchwork of state laws. For practice owners, this creates a landscape of both unprecedented opportunity and significant geographic disparity. The signal is clear: in the intricate world of healthcare consolidation, dermatology is operating by its own set of rules.

The Anatomy of a Resilient Market

The foundation of dermatology's investment appeal is its powerful market fundamentals. The U.S. dermatological services market, valued at approximately $63 billion in 2023, is projected to more than double to $128 billion by 2033, according to industry projections. This impressive 7.3% compound annual growth rate is fueled by non-negotiable demographic trends: an aging population requiring more complex skin care and the sobering statistic of nearly 9,500 new skin cancer diagnoses daily in the United States.

Unlike other medical specialties that are heavily reliant on fluctuating insurance reimbursements, many dermatology practices have built a resilient, hybrid business model. They blend medically necessary procedures with a significant and growing portfolio of cash-pay cosmetic services. This diversification provides a stable revenue stream that is less susceptible to reimbursement pressures, a feature highly prized by investors.

This inherent strength stands in stark contrast to the broader healthcare M&A environment. Data from PitchBook confirms the 16% drop in healthcare services deal count in early 2026, a slowdown attributed to rising interest rates, heightened regulatory scrutiny, and general economic uncertainty. Yet, as noted in TUSK's Q3 2026 Dermatology M&A Market Report, dermatology was one of the few subsegments where activity persisted, with buyers remaining aggressive for the right assets.

"Dermatology practices held their value in a quarter when most physician-services sectors experienced a softening of multiples, indicating high demand from buyers for quality operational dermatology practices," said Ryan Mingus, Managing Director and Partner at TUSK Practice Sales.

The Great Capital Refresh

A primary engine driving the current market is what the report identifies as a "recapitalization wave." The initial PE gold rush into dermatology, which peaked between 2016 and 2020, has now reached a natural maturation point. At least 25 major PE-backed dermatology platforms have been held for five or more years, the typical holding period for such investments.

These firms are now executing their next liquidity event, often selling their scaled-up platforms to larger PE funds in secondary buyouts or pursuing major refinancing. This process injects a massive infusion of fresh capital back into the market. Newly recapitalized platforms, such as Forefront Dermatology and Epiphany Dermatology, are now armed with new mandates and substantial funds to grow through acquisition. The focus has decisively shifted from building new platforms from scratch to executing strategic "add-on" acquisitions to bolster existing ones.

This dynamic has created a seller's market for a specific type of practice: well-run, diversified, and profitable. According to the report, buyers are competing fiercely for practices with an EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of over $500,000 that offer a mix of medical, surgical, and cosmetic services.

"What has changed for dermatology practices pursuing a sale is the leverage owners have in a volatile environment," Mingus explained. "With at least 25 platforms now five or more years into their hold, you have well-funded buyers who need to grow through acquisition competing over a much smaller pool of practices than in other healthcare specialties. For the dermatologist who has built a successful dermatology practice with $500K+ of EBITDA, that scarcity is real leverage."

A Widening Regulatory Divide

While capital flows freely, its direction is increasingly being dictated by state legislatures. A growing patchwork of state laws governing the "corporate practice of medicine" (CPOM)—doctrines designed to prevent corporations from controlling clinical decisions—is creating a fractured M&A map. Buyers are becoming hesitant to enter states with new or pending legislation that adds layers of red tape to ownership and operational structures.

The TUSK report specifically cites new laws like Oregon's SB 951 and California's SB 351, with similar bills pending in at least nine other states, as key factors steering investment. Private equity firms, which typically operate through Management Services Organizations (MSOs) that handle the business aspects of a practice while leaving clinical decisions to physicians, are now carefully weighing the regulatory risk associated with each state. The result is a concentration of buyer demand in states perceived as more business-friendly, leaving practice owners in more restrictive states with fewer potential partners and less competitive tension to drive up valuations. This trend underscores that in today's market, geography matters more than ever.

Navigating a Disciplined Market

Despite the intense competition for quality assets, the era of easy money is over. With the Federal Reserve holding interest rates in the 3.50% to 3.75% range, the cost of debt used to finance these acquisitions is significant. This economic reality has instilled a new level of discipline in buyers. They are more selective, conducting deeper due diligence and placing greater emphasis on sophisticated deal structures.

For sellers, this means that an attractive offer today is often a complex mosaic of components beyond just cash at closing. It may include rolled equity in the new parent company, performance-based earn-outs, and various escrow arrangements. Understanding these levers is critical for practice owners looking to maximize their outcome.

The outlook for the remainder of 2026 remains strong, driven by the sheer necessity for newly capitalized platforms to deploy their funds and grow. "Buyers still need quality practices, and the groups sitting on aged platforms cannot wait forever," Mingus added. "We expect acquisition activity to pick up through the back half of 2026 as recapitalized groups put fresh capital to work. Dermatology practice owners should be prepared to understand their practice's opportunity in today's market to make informed decisions."